RT Conference Proceedings
T1 Ribociclib (RIB) plus letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
A1 Cottu, P. H.
A1 Ring, A.
A1 Marchetti, P.
A1 Cardoso, F.
A1 Salvador, J.
A1 Neven, P.
A1 Papazisis, K.
A1 Campone, M.
A1 Bachelot, T.
A1 Menon-Singh, L.
A1 Wu, J.
A1 Zhou, K.
A1 De laurentiis, M.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-09-01
LK https://hdl.handle.net/10668/27218
UL https://hdl.handle.net/10668/27218
LA en
DS RISalud
RD Apr 10, 2025